摘要
目的观察心脉隆联合曲美他嗪对慢性心力衰竭(CHF)患者心功能及血浆B型脑尿钠肽(BNP)水平的影响。方法方便选择2016年1月—2017年1月该院125例心功能III～IV级CHF患者,随机分为对照组(40例)、治疗组1(42例)、治疗组2(43例),3组均给予血管转换酶抑制剂(ACEI)或血管紧张素II受体阻断剂(ARB)、β受体阻滞剂、醛固酮受体拮抗剂、利尿剂、洋地黄剂、扩张血管等常规抗心力衰竭药物。对照组采用常规抗心力衰竭,治疗组1在对照组基础上加用心脉隆,治疗组2在加用心脉隆联合口服曲美他嗪治疗,10 d为1个疗程,观察3组患者治疗4周后左心室射血分数(LVEF)、左心室舒张末期内径(LVDd)、6 min步行距离(6-WMD)及N端B型脑钠肽前体(NT-proBNP)水平。结果对照组、治疗组1、治疗组2治疗后LVEF分别为(43.86±2.69)%,(47.43±2.87)%,(50.27±1.85)%;LVDd分别为(47.66±6.93)mm,(43.67±4.53)mm(42.19±5.36)mm;6-WMD分别为(342.66±50.44)m,(418.78±35.86)m,(444.55±23.30)m; NT-proBNP分别为(3 092±435)ng/L,(1 963±384)ng/L,(1 223±247)ng/L。3组心功能指标治疗前差异无统计学意义(t=0.221、0.812、1.032、1.822,P>0.05),治疗后均明显改善(t=6.287、5.878、5.922、5.891,P<0.05)。治疗组2心功能指标及血浆BNP均较治疗组1、对照组改善更加明显(t=4.285、5.744、6.053、6.801,P<0.05)。结论在常规治疗基础上加用心脉隆注射液联合曲美他嗪治疗慢性心力衰竭,可明显提高疗效,降低血浆BNP水平,改善心功能。
Objective To observe the effects of Xinmailong combined with trimetazidine on cardiac function and plasma Btype natriuretic peptide (BNP) levels in patients with chronic heart failure (CHF). Methods From January 2016 to January 2017, 125 patients with grade III-IV CHF in our hospital were convenient selected and randomly divided into control group (40 cases), treatment group 1 (42 cases), and treatment group 2 (43 cases). All three groups were given vascular transduc-tase inhibitor (ACEI) or angiotensin II receptor blocker (ARB), beta blocker, aldosterone receptor antagonist, diuretic, digi-talis, dilated blood vessels and the like anti-heart failure drugs. The control group was treated with conventional anti-heart failure. The treatment group 1 was treated with Xinmailong on the basis of the control group, and the treatment group 2 was treated with Xinmailong combined with oral trimetazidine. After 10 days, the patients in the three groups were treated for 4 weeks. Ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVDd), 6 min walking distance (6- WMD), and N-terminal B-brain natriuretic peptide (NT-proBNP) levels were observed. Results The LVEF of the control group, the treatment group 1 and the treatment group 2 were (43.86±2.69)%,(47.43±2.87)%,(50.27±1.85)%, and LVDd were (47.66±6.93) mm,(43.67±4.53) mm,(42.19±5.36) mm;6-WMD were (342.66±50.44) m,(418.78±35.86) m,(444.55± 23.30) m;NT-proBNP was (3 092±435) ng/L,(1 963±384) ng/L,(1 223±247) ng/L. There were no significant differences in the three groups of cardiac function indicators before treatment (t=0.221, 0.812, 1.032,1.822,P>0.05), and were significantly improved after treatment (t=6.287, 5.878, 5.922, 5.891, P<0.05. The treatment group 2 cardiac function index and plasma BNP were more obvious than the treatment group 1 and the control group (t=4.285, 5.744, 6.053,6.801, P<0.05). Conclu-sion The addition of Xinmailong injection combined with trimetazidine in the treatment of chronic heart failure on the basis of c
作者
嵇诚
朱文龙
张立新
马涛
王春梅
邸亮
李小玉
JI Cheng;ZHU Wen-long;ZHANG Li-xin;MA Tao;WANG Chun-mei;DI Liang;LI Xiao-yu(Department of Cardiology, Haigang Hospital, Qinhuangdao, Hebei Province, 066000 China)
出处
《中外医疗》
2019年第8期140-142,共3页
China & Foreign Medical Treatment
基金
秦皇岛市科学技术研究与发展计划:心脉隆联合曲美他嗪治疗对慢性心力衰竭的疗效观察(201703A189)
关键词
曲美他嗪
心力衰竭
心功能
B型脑尿钠肽
Trimetazidine
Heart failure
Heart function
Type B brain natriuretic peptide
